| 1 | Expanded profiling of WD repeat domain 5 inhibitors reveals actionable strategies for the treatment of hematologic malignancies. (Meyer CT, Smith BN, Wang J, Teuscher KB, Grieb BC, Howard GC, Silver AJ, Lorey SL, Stott GM, Moore WJ, Lee T, Savona MR, Weissmiller AM, Liu Q, Quaranta V, Fesik SW, Tansey WP) Proc Natl Acad Sci U S A 2024 Aug 27;121(35):e2408889121 |
| 1 | Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial. (Roeker LE, Woyach JA, Cheah CY, Coombs CC, Shah NN, Wierda WG, Patel MR, Lamanna N, Tsai DE, Nair B, Wang C, Zhao X, Liu D, Radtke D, Chapman S, Marella N, McNeely SC, Brown JR) Blood 2024 Sep 26;144(13):1374-1386 2 Citations |
| 5 | A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia. (Murthy GSG, Saliba AN, Szabo A, Harrington A, Abedin S, Carlson K, Michaelis L, Runaas L, Baim A, Hinman A, Maldonado-Schmidt S, Venkatachalam A, Flatten KS, Peterson KL, Schneider PA, Litzow M, Kaufmann SH, Atallah E) Haematologica 2024 Sep 01;109(9):2864-2872 2 Citations |
| 1 | Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). (Badar T, Nanaa A, Atallah E, Shallis RM, Guilherme SCC, Goldberg AD, Saliba AN, Patel A, Bewersdorf JP, DuVall AS, Bradshaw D, Abaza Y, Murthy GSG, Palmisiano N, Zeidan AM, Kota V, Litzow MR) Blood Cancer J 2024 Feb 20;14(1):32 4 Citations |
| 3 | Argatroban Use in Pediatric Patients Supported by Paracorporeal Ventricular Assist Devices. (Tuttle MG, Yan K, Zhang J, Niebler RA) ASAIO J 2024 Mar 01;70(3):224-229 |
| 2 | The Effect of Udenafil on Heart Rate and Blood Pressure in Adolescents With the Fontan Circulation. (Edelson JB, Zak V, Goldberg D, Fleming G, Mackie AS, Patel JK, Files M, Downing T, Richmond M, Acheampong B, Cartoski M, Detterich J, McCrindle B, McHugh K, Hansen JE, Wagner J, Maria MD, Weingarten A, Nowlen T, Yoon JK, Kim GB, Williams R, Whitehill R, Kirkpatrick E, Yin S, Ermis P, Lubert AM, Stylianou M, Freemon D, Hu C, Garuba OD, Frommelt P, Goldstein BH, Paridon S, Garg R, Pediatric Heart Network Investigators) Am J Cardiol 2024 Jan 01;210:183-187 1 Citation |
| 1 | Efficacy and Risk Stratification of Janus Kinase Inhibitors in the Treatment of Moderate-to-Severe Atopic Dermatitis. (Narla S, Silverberg JI) Dermatitis 2024;35(S1):S24-S38 1 Citation |
| 1 | The Fontan Udenafil Exercise Longitudinal Trial: Subgroup Analysis. (Goldberg DJ, Hu C, Lubert AM, Rathod RH, Penny DJ, Petit CJ, Schumacher KR, Ginde S, Williams RV, Yoon JK, Kim GB, Nowlen TT, DiMaria MV, Frischhertz BP, Wagner JB, McHugh KE, McCrindle BW, Cartoski MJ, Detterich JA, Yetman AT, John AS, Richmond ME, Yung D, Payne RM, Mackie AS, Davis CK, Shahanavaz S, Hill KD, Almaguer M, Zak V, McBride MG, Goldstein BH, Pearson GD, Paridon SM, Pediatric Heart Network Investigators) Pediatr Cardiol 2023 Dec;44(8):1691-1701 2 Citations |
| 1 | Venetoclax-based Treatment as Frontline Therapy for Chronic Lymphocytic Leukemia. (Guru Murthy GS, Atallah E) Hematol Oncol Stem Cell Ther 2023 May 23;16(4):346-350 1 Citation |
| 1 | Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. (Siddiqi T, Maloney DG, Kenderian SS, Brander DM, Dorritie K, Soumerai J, Riedell PA, Shah NN, Nath R, Fakhri B, Stephens DM, Ma S, Feldman T, Solomon SR, Schuster SJ, Perna SK, Tuazon SA, Ou SS, Papp E, Peiser L, Chen Y, Wierda WG) Lancet 2023 Aug 19;402(10402):641-654 53 Citations |
| 1 | Impact of Udenafil on Echocardiographic Indices of Single Ventricle Size and Function in FUEL Study Participants. (Di Maria MV, Goldberg DJ, Zak V, Hu C, Lubert AM, Dragulescu A, Mackie AS, McCrary A, Weingarten A, Parthiban A, Goot B, Goldstein BH, Taylor C, Lindblade C, Petit CJ, Spurney C, Harrild DM, Urbina EM, Schuchardt E, Beom Kim G, Kyoung Yoon J, Colombo JN, Files MD, Schoessling M, Ermis P, Wong PC, Garg R, Swanson SK, Menon SC, Srivastava S, Thorsson T, Johnson TR, Krishnan US, Paridon SM, Frommelt PC, Pediatric Heart Network) Circ Cardiovasc Imaging 2022 Nov;15(11):e013676 2 Citations |
| 1 | Reported Pericardial Toxicities Associated with Acute Myelogenous Leukemia Treatments: A Pharmacovigilance Analysis of the FDA Adverse Reporting Database. (Janus SE, Heisler AC, Al Jammal M, Chahine N, Chami T, Hajjari J, Mously H, Badhwar A, Arora S, Al-Juhaishi T, Al-Kindi SG, Hoit BD) Curr Probl Cardiol 2022 Nov;47(11):101345 3 Citations |
| 4 | Oral and Inhaled Fosamprenavir Reverses Pepsin-Induced Damage in a Laryngopharyngeal Reflux Mouse Model. (Johnston N, Samuels TL, Goetz CJ, Arnold LA, Smith BC, Seabloom D, Wuertz B, Ondrey F, Wiedmann TS, Vuksanovic N, Silvaggi NR, MacKinnon AC, Miller J, Bock J, Blumin JH) Laryngoscope 2023 Jan;133 Suppl 1(Suppl 1):S1-S11 5 Citations |
| 1 | Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. (Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, Piruzeli MLB, Goldman JD, Alatorre-Alexander J, de Cassia Pellegrini R, Estrada V, Som M, Cardoso A, Chakladar S, Crowe B, Reis P, Zhang X, Adams DH, Ely EW, COV-BARRIER Study Group) Lancet Respir Med 2021 Dec;9(12):1407-1418 501 Citations |
| 1 | Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas. (Schulte B, Mohindra N, Milhem M, Attia S, Robinson S, Monga V, Hirbe AC, Oppelt P, Charlson J, Helenowski I, Abbinanti S, Cehic R, Okuno S, Van Tine BA, Agulnik M) Br J Cancer 2021 Aug;125(4):528-533 13 Citations |
| 1 | Utilization and Outcomes of Children Treated with Direct Thrombin Inhibitors on Paracorporeal Ventricular Assist Device Support. (VanderPluym CJ, Cantor RS, Machado D, Boyle G, May L, Griffiths E, Niebler RA, Lorts A, Rossano J, Sutcliffe DL, Lytrivi ID, Buchholz H, Fynn-Thompson F, Hawkins B, Conway J) ASAIO J 2020 Aug;66(8):939-945 64 Citations |
| 1 | Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis. (Putman M, Chock YPE, Tam H, Kim AHJ, Sattui SE, Berenbaum F, Danila MI, Korsten P, Sanchez-Alvarez C, Sparks JA, Coates LC, Palmerlee C, Peirce A, Jayatilleke A, Johnson SR, Kilian A, Liew J, Prokop LJ, Murad MH, Grainger R, Wallace ZS, Duarte-García A, COVID-19 Global Rheumatology Alliance) Arthritis Rheumatol 2021 Jan;73(1):36-47 49 Citations |
| 1 | Thrombocytopenia and Thromboses in Myocardial Infarction Associated with Eptifibatide-Dependent Activating Antiplatelet Antibodies. (Puram RV, Erdil RM, Weber BN, Knelson EH, Van Beuningen AM, Wallwork R, Gilyard SN, Curtis BR, Ranganathan R, Leaf RK, Malhotra R) Thromb Haemost 2020 Jul;120(7):1137-1141 4 Citations |
| 1 | Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. (Mato AR, Roeker LE, Jacobs R, Hill BT, Lamanna N, Brander D, Shadman M, Ujjani CS, Yazdy MS, Perini GF, Pinilla-Ibarz JA, Barrientos J, Skarbnik AP, Torka P, Pu JJ, Pagel JM, Gohil S, Fakhri B, Choi M, Coombs CC, Rhodes J, Barr PM, Portell CA, Parry H, Garcia CA, Whitaker KJ, Winter AM, Sitlinger A, Khajavian S, Grajales-Cruz AF, Isaac KM, Shah P, Akhtar OS, Pocock R, Lam K, Voorhees TJ, Schuster SJ, Rodgers TD, Fox CP, Martinez-Calle N, Munir T, Bhavsar EB, Bailey N, Lee JC, Weissbrot HB, Nabhan C, Goodfriend JM, King AC, Zelenetz AD, Dorsey C, Bigelow K, Cheson BD, Allan JN, Eyre TA) Clin Cancer Res 2020 Jul 15;26(14):3589-3596 89 Citations |
| 1 | BCL-2 inhibition and AML: can we best Darwin? (Michaelis LC) Blood 2020 Mar 12;135(11):781-782 2 Citations |
| 1 | Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer. (Shahjehan F, Kamatham S, Chandrasekharan C, Kasi PM) Drugs Today (Barc) 2019 Nov;55(11):683-693 11 Citations |
| 2 | Results of the FUEL Trial. (Goldberg DJ, Zak V, Goldstein BH, Schumacher KR, Rhodes J, Penny DJ, Petit CJ, Ginde S, Menon SC, Kim SH, Kim GB, Nowlen TT, DiMaria MV, Frischhertz BP, Wagner JB, McHugh KE, McCrindle BW, Shillingford AJ, Sabati AA, Yetman AT, John AS, Richmond ME, Files MD, Payne RM, Mackie AS, Davis CK, Shahanavaz S, Hill KD, Garg R, Jacobs JP, Hamstra MS, Woyciechowski S, Rathge KA, McBride MG, Frommelt PC, Russell MW, Urbina EM, Yeager JL, Pemberton VL, Stylianou MP, Pearson GD, Paridon SM, Pediatric Heart Network Investigators) Circulation 2020 Feb 25;141(8):641-651 94 Citations |
| 1 | Structure-based mechanism of cysteinyl leukotriene receptor inhibition by antiasthmatic drugs. (Luginina A, Gusach A, Marin E, Mishin A, Brouillette R, Popov P, Shiriaeva A, Besserer-Offroy É, Longpré JM, Lyapina E, Ishchenko A, Patel N, Polovinkin V, Safronova N, Bogorodskiy A, Edelweiss E, Hu H, Weierstall U, Liu W, Batyuk A, Gordeliy V, Han GW, Sarret P, Katritch V, Borshchevskiy V, Cherezov V) Sci Adv 2019 Oct;5(10):eaax2518 66 Citations |
| 1 | A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers. (Kurzrock R, Ball DW, Zahurak ML, Nelkin BD, Subbiah V, Ahmed S, O'Connor A, Karunsena E, Parkinson RM, Bishop JA, Ha Y, Sharma R, Gocke CD, Zinner R, Rudek MA, Sherman SI, Azad NS) Clin Cancer Res 2019 Sep 15;25(18):5475-5484 17 Citations |
| 1 | A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. (Mato AR, Roeker LE, Eyre TA, Nabhan C, Lamanna N, Hill BT, Brander DM, Barr PM, Lansigan F, Cheson BD, Singavi AK, Yazdy MS, Shah NN, Allan JN, Bhavsar EB, Rhodes J, Kennard K, Schuster SJ, Williams AM, Skarbnik AP, Goy AH, Goodfriend JM, Dorsey C, Coombs CC, Tuncer H, Ujjani CS, Jacobs R, Winter AM, Pagel JM, Bailey N, Schuh A, Shadman M, Sitlinger A, Weissbrot H, Muralikrishnan S, Zelenetz A, Kirkwood AA, Fox CP) Blood Adv 2019 May 28;3(10):1568-1573 25 Citations |
| 1 | Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. (Roeker LE, Fox CP, Eyre TA, Brander DM, Allan JN, Schuster SJ, Nabhan C, Hill BT, Shah NN, Lansigan F, Yazdy M, Cheson BD, Lamanna N, Singavi AK, Coombs CC, Barr PM, Skarbnik AP, Shadman M, Ujjani CS, Tuncer HH, Winter AM, Rhodes J, Dorsey C, Morse H, Kabel C, Pagel JM, Williams AM, Jacobs R, Goy A, Muralikrishnan S, Pearson L, Sitlinger A, Bailey N, Schuh A, Kirkwood AA, Mato AR) Clin Cancer Res 2019 Jul 15;25(14):4264-4270 63 Citations |
| 1 | Venetoclax in AML: aiming for "just right". (Michaelis LC) Blood 2019 Jan 03;133(1):3-4 4 Citations |
| 1 | Design and rationale of the Fontan Udenafil Exercise Longitudinal (FUEL) trial. (Goldberg DJ, Zak V, Goldstein BH, McCrindle BW, Menon SC, Schumacher KR, Payne RM, Rhodes J, McHugh KE, Penny DJ, Trachtenberg F, Hamstra MS, Richmond ME, Frommelt PC, Files MD, Yeager JL, Pemberton VL, Stylianou MP, Pearson GD, Paridon SM, Pediatric Heart Network Investigators) Am Heart J 2018 Jul;201:1-8 22 Citations |
| 1 | Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. (Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS, Hill BT, Lamanna N, Lansigan F, Jacobs R, Shadman M, Skarbnik AP, Pu JJ, Barr PM, Sehgal AR, Cheson BD, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Goy A, Winter AM, Garcia C, Kennard K, Isaac K, Dorsey C, Gashonia LM, Singavi AK, Roeker LE, Zelenetz A, Williams A, Howlett C, Weissbrot H, Ali N, Khajavian S, Sitlinger A, Tranchito E, Rhodes J, Felsenfeld J, Bailey N, Patel B, Burns TF, Yacur M, Malhotra M, Svoboda J, Furman RR, Nabhan C) Haematologica 2018 Sep;103(9):1511-1517 136 Citations |
| 1 | Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. (Brown JR, Hamadani M, Hayslip J, Janssens A, Wagner-Johnston N, Ottmann O, Arnason J, Tilly H, Millenson M, Offner F, Gabrail NY, Ganguly S, Ailawadhi S, Kasar S, Kater AP, Doorduijn JK, Gao L, Lager JJ, Wu B, Egile C, Kersten MJ) Lancet Haematol 2018 Apr;5(4):e170-e180 48 Citations |
| 2 | A Rationally Designed Agonist Defines Subfamily IIIA Abscisic Acid Receptors As Critical Targets for Manipulating Transpiration. (Vaidya AS, Peterson FC, Yarmolinsky D, Merilo E, Verstraeten I, Park SY, Elzinga D, Kaundal A, Helander J, Lozano-Juste J, Otani M, Wu K, Jensen DR, Kollist H, Volkman BF, Cutler SR) ACS Chem Biol 2017 Nov 17;12(11):2842-2848 56 Citations |
| 1 | The Use of Eptifibatide Alone or in Combination With Heparin or Argatroban for Suspected Thrombosis in Patients With Left Ventricular Assist Devices. (Bitar A, Vijayakrishnan R, Lenneman A, Birks E, Massey T, Slaughter M, Abramov D) Artif Organs 2017 Dec;41(12):1092-1098 6 Citations |
| 1 | Use of medical expulsive therapy in children: An assessment of nationwide practice patterns and outcomes. (Ellison JS, Merguerian PA, Fu BC, Holt SK, Lendvay TS, Gore JL, Shnorhavorian M) J Pediatr Urol 2017 Oct;13(5):509.e1-509.e7 17 Citations |
| 1 | Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma. (Subbiah V, Meyer C, Zinner R, Meric-Bernstam F, Zahurak ML, O'Connor A, Roszik J, Shaw K, Ludwig JA, Kurzrock R, Azad NA) Clin Cancer Res 2017 Aug 01;23(15):4027-4034 37 Citations |
| 1 | A novel TRPV4-specific agonist inhibits monocyte adhesion and atherosclerosis. (Xu S, Liu B, Yin M, Koroleva M, Mastrangelo M, Ture S, Morrell CN, Zhang DX, Fisher EA, Jin ZG) Oncotarget 2016 Jun 21;7(25):37622-37635 57 Citations |
| 1 | Current state of hematopoietic cell transplantation in CLL as smart therapies emerge. (Kharfan-Dabaja MA, El-Asmar J, Awan FT, Hamadani M, Ayala E) Best Pract Res Clin Haematol 2016 Mar;29(1):54-66 6 Citations |
| 1 | A dual COX-2/sEH inhibitor improves the metabolic profile and reduces kidney injury in Zucker diabetic fatty rat. (Hye Khan MA, Hwang SH, Sharma A, Corbett JA, Hammock BD, Imig JD) Prostaglandins Other Lipid Mediat 2016 Sep;125:40-7 37 Citations |
| 1 | FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. (Haemmerle M, Bottsford-Miller J, Pradeep S, Taylor ML, Choi HJ, Hansen JM, Dalton HJ, Stone RL, Cho MS, Nick AM, Nagaraja AS, Gutschner T, Gharpure KM, Mangala LS, Rupaimoole R, Han HD, Zand B, Armaiz-Pena GN, Wu SY, Pecot CV, Burns AR, Lopez-Berestein G, Afshar-Kharghan V, Sood AK) J Clin Invest 2016 May 02;126(5):1885-96 99 Citations |
| 1 | Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer. (Yang W, Hosford SR, Dillon LM, Shee K, Liu SC, Bean JR, Salphati L, Pang J, Zhang X, Nannini MA, Demidenko E, Bates D, Lewis LD, Marotti JD, Eastman AR, Miller TW) Clin Cancer Res 2016 May 01;22(9):2250-60 27 Citations |
| 1 | First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. (Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock R) Clin Cancer Res 2016 Apr 15;22(8):1932-9 81 Citations |
| 1 | A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors. (Henary H, George GC, Wheler J, Naing A, Piha-Paul S, Fu S, Mistry R, Zinner R, Kurzrock R, Hong DS) Cancer Chemother Pharmacol 2015 Sep;76(3):597-603 2 Citations |
| 1 | Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. (Phan AT, Halperin DM, Chan JA, Fogelman DR, Hess KR, Malinowski P, Regan E, Ng CS, Yao JC, Kulke MH) Lancet Oncol 2015 Jun;16(6):695-703 108 Citations |
| 1 | Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. (Rodrigues HV, Ke D, Lim J, Stephen B, Bellido J, Janku F, Zinner R, Tsimberidou A, Hong D, Piha-Paul S, Fu S, Naing A, Subbiah V, Karp D, Falchook G, Kurzrock R, Wheler J) Invest New Drugs 2015 Jun;33(3):700-9 13 Citations |
| 1 | Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. (Fu S, Hou MM, Naing A, Janku F, Hess K, Zinner R, Subbiah V, Hong D, Wheler J, Piha-Paul S, Tsimberidou A, Karp D, Araujo D, Kee B, Hwu P, Wolff R, Kurzrock R, Meric-Bernstam F) Ann Oncol 2015 May;26(5):1012-1018 55 Citations |
| 1 | Dasabuvir : a new direct antiviral agent for the treatment of hepatitis C. (Trivella JP, Gutierrez J, Martin P) Expert Opin Pharmacother 2015 Mar;16(4):617-24 19 Citations |
| 3 | Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation. (Cheng G, Zielonka J, McAllister D, Tsai S, Dwinell MB, Kalyanaraman B) Br J Cancer 2014 Jul 08;111(1):85-93 71 Citations |
| 1 | Structure of the human P2Y12 receptor in complex with an antithrombotic drug. (Zhang K, Zhang J, Gao ZG, Zhang D, Zhu L, Han GW, Moss SM, Paoletta S, Kiselev E, Lu W, Fenalti G, Zhang W, Müller CE, Yang H, Jiang H, Cherezov V, Katritch V, Jacobson KA, Stevens RC, Wu B, Zhao Q) Nature 2014 May 01;509(7498):115-8 314 Citations |
| 1 | Expansion of the neonatal platelet mass is achieved via an extension of platelet lifespan. (Liu ZJ, Hoffmeister KM, Hu Z, Mager DE, Ait-Oudhia S, Debrincat MA, Pleines I, Josefsson EC, Kile BT, Italiano J Jr, Ramsey H, Grozovsky R, Veng-Pedersen P, Chavda C, Sola-Visner M) Blood 2014 May 29;123(22):3381-9 56 Citations |
| 1 | The progressive ankylosis gene product ANK regulates extracellular ATP levels in primary articular chondrocytes. (Rosenthal AK, Gohr CM, Mitton-Fitzgerald E, Lutz MK, Dubyak GR, Ryan LM) Arthritis Res Ther 2013 Oct 17;15(5):R154 37 Citations |
| 1 | Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. (Kang Y, Hu W, Ivan C, Dalton HJ, Miyake T, Pecot CV, Zand B, Liu T, Huang J, Jennings NB, Rupaimoole R, Taylor M, Pradeep S, Wu SY, Lu C, Wen Y, Huang J, Liu J, Sood AK) J Natl Cancer Inst 2013 Oct 02;105(19):1485-95 158 Citations |
| 2 | Activation of dimeric ABA receptors elicits guard cell closure, ABA-regulated gene expression, and drought tolerance. (Okamoto M, Peterson FC, Defries A, Park SY, Endo A, Nambara E, Volkman BF, Cutler SR) Proc Natl Acad Sci U S A 2013 Jul 16;110(29):12132-7 248 Citations |
| 1 | Differential control of calcium homeostasis and vascular reactivity by Ca2+/calmodulin-dependent kinase II. (Prasad AM, Nuno DW, Koval OM, Ketsawatsomkron P, Li W, Li H, Shen FY, Joiner ML, Kutschke W, Weiss RM, Sigmund CD, Anderson ME, Lamping KG, Grumbach IM) Hypertension 2013 Aug;62(2):434-41 31 Citations |
| 1 | Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation. (Munoz J, Schlette E, Kurzrock R) J Clin Oncol 2013 Jul 10;31(20):e351-2 58 Citations |
| 1 | Melanoma brain metastasis: overview of current management and emerging targeted therapies. (Fonkem E, Uhlmann EJ, Floyd SR, Mahadevan A, Kasper E, Eton O, Wong ET) Expert Rev Neurother 2012 Oct;12(10):1207-15 64 Citations |
| 1 | Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma. (Boyd KP, Vincent B, Andea A, Conry RM, Hughey LC) J Am Acad Dermatol 2012 Dec;67(6):1375-9 46 Citations |
| 1 | Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. (Angiolillo DJ, Welsh RC, Trenk D, Neumann FJ, Conley PB, McClure MW, Stephens G, Kochman J, Jennings LK, Gurbel PA, Wójcik J, Dabrowski M, Saucedo JF, Stumpf J, Buerke M, Broderick S, Harrington RA, Rao SV) Circ Cardiovasc Interv 2012 Jun;5(3):347-56 30 Citations |
| 1 | Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. (Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, Hamid O, Infante JR, Millward M, Pavlick AC, O'Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF) Lancet 2012 May 19;379(9829):1893-901 824 Citations |
| 1 | Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. (Chu EY, Wanat KA, Miller CJ, Amaravadi RK, Fecher LA, Brose MS, McGettigan S, Giles LR, Schuchter LM, Seykora JT, Rosenbach M) J Am Acad Dermatol 2012 Dec;67(6):1265-72 153 Citations |
| 1 | Effects of rosuvastatin and atorvastatin on renal function: meta-analysis. (Wu Y, Wang Y, An C, Dong Z, Liu H, Zhang Y, Zhang M, An F) Circ J 2012;76(5):1259-66 29 Citations |
| 2 | Upregulation of mucosal 5-HT3 receptors is involved in restoration of colonic transit after pelvic nerve transection. (Gribovskaja-Rupp I, Takahashi T, Ridolfi T, Kosinski L, Ludwig K) Neurogastroenterol Motil 2012 May;24(5):472-8, e218 5 Citations |
| 1 | Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance. (Kennedy SP, Barnas GP, Schmidt MJ, Glisczinski MS, Paniagua AC) J Clin Lipidol 2011;5(4):308-15 43 Citations |
| 1 | Phase I/II trial of a COX-2 inhibitor with limited field radiation for intermediate prognosis patients who have locally advanced non-small-cell lung cancer: radiation therapy oncology group 0213. (Gore E, Bae K, Langer C, Extermann M, Movsas B, Okunieff P, Videtic G, Choy H) Clin Lung Cancer 2011 Mar;12(2):125-30 25 Citations |
| 1 | 20-Iodo-14,15-epoxyeicosa-8(Z)-enoyl-3-azidophenylsulfonamide: photoaffinity labeling of a 14,15-epoxyeicosatrienoic acid receptor. (Chen Y, Falck JR, Manthati VL, Jat JL, Campbell WB) Biochemistry 2011 May 10;50(18):3840-8 45 Citations |
| 1 | Inhibition of JAK2 signaling by TG101209 enhances radiotherapy in lung cancer models. (Sun Y, Moretti L, Giacalone NJ, Schleicher S, Speirs CK, Carbone DP, Lu B) J Thorac Oncol 2011 Apr;6(4):699-706 |
| 1 | A patient with 'spontaneous' heparin-induced thrombocytopenia and thrombosis after undergoing knee replacement. (Mallik A, Carlson KB, DeSancho MT) Blood Coagul Fibrinolysis 2011 Jan;22(1):73-5 23 Citations |
| 2 | Structural basis for selective activation of ABA receptors. (Peterson FC, Burgie ES, Park SY, Jensen DR, Weiner JJ, Bingman CA, Chang CE, Cutler SR, Phillips GN Jr, Volkman BF) Nat Struct Mol Biol 2010 Sep;17(9):1109-13 98 Citations |
| 2 | TRPV4-mediated endothelial Ca2+ influx and vasodilation in response to shear stress. (Mendoza SA, Fang J, Gutterman DD, Wilcox DA, Bubolz AH, Li R, Suzuki M, Zhang DX) Am J Physiol Heart Circ Physiol 2010 Feb;298(2):H466-76 259 Citations |
| 1 | Abscisic acid inhibits type 2C protein phosphatases via the PYR/PYL family of START proteins. (Park SY, Fung P, Nishimura N, Jensen DR, Fujii H, Zhao Y, Lumba S, Santiago J, Rodrigues A, Chow TF, Alfred SE, Bonetta D, Finkelstein R, Provart NJ, Desveaux D, Rodriguez PL, McCourt P, Zhu JK, Schroeder JI, Volkman BF, Cutler SR) Science 2009 May 22;324(5930):1068-71 2259 Citations |
| 2 | Differential effects of transient receptor vanilloid one (TRPV1) antagonists in acid-induced excitation of esophageal vagal afferent fibers of rats. (Peles S, Medda BK, Zhang Z, Banerjee B, Lehmann A, Shaker R, Sengupta JN) Neuroscience 2009 Jun 30;161(2):515-25 37 Citations |
| 1 | Xenon induces late cardiac preconditioning in vivo: a role for cyclooxygenase 2? (Weber NC, Frässdorf J, Ratajczak C, Grueber Y, Schlack W, Hollmann MW, Preckel B) Anesth Analg 2008 Dec;107(6):1807-13 38 Citations |
| 1 | Constitutive activity at the cannabinoid CB1 receptor is required for behavioral response to noxious chemical stimulation of TRPV1: antinociceptive actions of CB1 inverse agonists. (Fioravanti B, De Felice M, Stucky CL, Medler KA, Luo MC, Gardell LR, Ibrahim M, Malan TP Jr, Yamamura HI, Ossipov MH, King T, Lai J, Porreca F, Vanderah TW) J Neurosci 2008 Nov 05;28(45):11593-602 78 Citations |
| 1 | Endogenous ghrelin and 5-HT regulate interdigestive gastrointestinal contractions in conscious rats. (Taniguchi H, Ariga H, Zheng J, Ludwig K, Mantyh C, Pappas TN, Takahashi T) Am J Physiol Gastrointest Liver Physiol 2008 Aug;295(2):G403-11 31 Citations |
| 1 | The role of transient receptor potential vanilloid 1 in mechanical and chemical visceral hyperalgesia following experimental colitis. (Miranda A, Nordstrom E, Mannem A, Smith C, Banerjee B, Sengupta JN) Neuroscience 2007 Sep 21;148(4):1021-32 141 Citations |
| 1 | Darunavir: a second-generation protease inhibitor. (Busse KH, Penzak SR) Am J Health Syst Pharm 2007 Aug 01;64(15):1593-602 20 Citations |
| 1 | Celecoxib toxicity is cell cycle phase specific. (Bock JM, Menon SG, Sinclair LL, Bedford NS, Goswami PC, Domann FE, Trask DK) Cancer Res 2007 Apr 15;67(8):3801-8 37 Citations |
| 1 | Relative non-steroidal anti-inflammatory drug (NSAID) antiproliferative activity is mediated through p21-induced G1 arrest and E2F inhibition. (Bock JM, Menon SG, Goswami PC, Sinclair LL, Bedford NS, Domann FE, Trask DK) Mol Carcinog 2007 Oct;46(10):857-64 18 Citations |
| 1 | Characterization of 14,15-epoxyeicosatrienoyl-sulfonamides as 14,15-epoxyeicosatrienoic acid agonists: use for studies of metabolism and ligand binding. (Yang W, Holmes BB, Gopal VR, Kishore RV, Sangras B, Yi XY, Falck JR, Campbell WB) J Pharmacol Exp Ther 2007 Jun;321(3):1023-31 42 Citations |
| 2 | Reduced expression of 15-lipoxygenase 2 in human head and neck carcinomas. (Wang D, Chen S, Feng Y, Yang Q, Campbell BH, Tang X, Campbell WB) Tumour Biol 2006;27(5):261-73 13 Citations |
| 1 | Inactivation of bacterial DD-peptidase by beta-sultams. (Llinás A, Ahmed N, Cordaro M, Laws AP, Frère JM, Delmarcelle M, Silvaggi NR, Kelly JA, Page MI) Biochemistry 2005 May 31;44(21):7738-46 33 Citations |
| 1 | Celecoxib and radiation therapy in non-small-cell lung cancer. (Gore E) Oncology (Williston Park) 2004 Dec;18(14 Suppl 14):10-4 23 Citations |
| 1 | Role of cyclooxygenase-2 in cytokine-induced beta-cell dysfunction and damage by isolated rat and human islets. (Heitmeier MR, Kelly CB, Ensor NJ, Gibson KA, Mullis KG, Corbett JA, Maziasz TJ) J Biol Chem 2004 Dec 17;279(51):53145-51 42 Citations |
| 1 | Combination treatment of PKD utilizing dual inhibition of EGF-receptor activity and ligand bioavailability. (Sweeney WE Jr, Hamahira K, Sweeney J, Garcia-Gatrell M, Frost P, Avner ED) Kidney Int 2003 Oct;64(4):1310-9 65 Citations |
| 1 | 14,15-epoxyeicosa-5(Z)-enoic-mSI: a 14,15- and 5,6-EET antagonist in bovine coronary arteries. (Gauthier KM, Jagadeesh SG, Falck JR, Campbell WB) Hypertension 2003 Oct;42(4):555-61 50 Citations |
| 1 | Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. (Widlansky ME, Price DT, Gokce N, Eberhardt RT, Duffy SJ, Holbrook M, Maxwell C, Palmisano J, Keaney JF Jr, Morrow JD, Vita JA) Hypertension 2003 Sep;42(3):310-5 147 Citations |
| 1 | Potentially significant drug interactions of class III antiarrhythmic drugs. (Yamreudeewong W, DeBisschop M, Martin LG, Lower DL) Drug Saf 2003;26(6):421-38 99 Citations |
| 1 | Comparison of cardioprotective efficacy of two thromboxane A2 receptor antagonists. (Ge ZD, Auchampach JA, Piper GM, Gross GJ) J Cardiovasc Pharmacol 2003 Mar;41(3):481-8 10 Citations |
| 1 | A novel inhibitor of tumor necrosis factor-alpha converting enzyme ameliorates polycystic kidney disease. (Dell KM, Nemo R, Sweeney WE Jr, Levin JI, Frost P, Avner ED) Kidney Int 2001 Oct;60(4):1240-8 64 Citations |
| 1 | The use of topical aqueous suppressants in the prevention of postoperative intraocular pressure elevation after pars plana vitrectomy with long-acting gas tamponade. (Mittra RA, Pollack JS, Dev S, Han DP, Mieler WF, Pulido JS, Connor TB) Ophthalmology 2000 Mar;107(3):588-92 28 Citations |
| 1 | Role of adenosine receptors in late preconditioning against myocardial stunning in conscious rabbits. (Maldonado C, Qiu Y, Tang XL, Cohen MV, Auchampach J, Bolli R) Am J Physiol 1997 Sep;273(3 Pt 2):H1324-32 53 Citations |
| 1 | Diabetic-induced endothelial dysfunction in rat aorta: role of hydroxyl radicals. (Pieper GM, Langenstroer P, Siebeneich W) Cardiovasc Res 1997 Apr;34(1):145-56 169 Citations |
| 1 | Adenosine A1 receptors, KATP channels, and ischemic preconditioning in dogs. (Auchampach JA, Gross GJ) Am J Physiol 1993 May;264(5 Pt 2):H1327-36 339 Citations |
